Form 4 for ENTX Entera Bio Ltd.
Accepted 2026-08-07 16:18:17 ET · period of report 2026-08-07 · accession 0001178913-26-003949 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-08-07 16:18 | 2026-08-07 | ENTX | Germano Geno J | Dir | A - Grant | $0.00 | +25.0K | 65.0K | +63% | $0 |
| DM | 2026-08-07 16:18 | 2026-08-07 | ENTX | Germano Geno J | Dir | A - Grant | $0.00 | +93.0K | 43.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares, par value NIS 0.0000769 per share | 2026-08-07 | A | A | 25,014 | $0.00 | 65,014 | D | — | — | (F1) The Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Person in lieu of the cash fees the Reporting Person was entitled to for services rendered as a director of the Company for the first quarter and second quarter of 2026. This grant of shares was approved by the Board on August 5, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the shares, which occurred on August 7, 2026. |
| 2 | Derivative | Stock Option (right to buy) | 2026-08-07 | A | A | 50,000 | $0.00 | 50,000 | D | $1.37 · — to 2036-05-07 | 50,000 Ordinary Shares, par value NIS 0.0000769 per share | (F2) Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a three year period which began on February 4, 2026, with one-third of the options vesting on February 4, 2027 and the remaining two-thirds vesting ratably on a quarterly basis over the remaining two-year period, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan (the "Plan")). |
| 3 | Derivative | Stock Option (right to buy) | 2026-08-07 | A | A | 43,014 | $0.00 | 43,014 | D | $1.37 · — to 2036-05-07 | 43,014 Ordinary Shares, par value NIS 0.0000769 per share | (F3) Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest on a quarterly basis over a one-year period that began on February 4, 2026, subject to full acceleration upon a Change in Control (as defined in the Plan). |